ClinVar Miner

Submissions for variant NM_000168.6(GLI3):c.3762T>G (p.Tyr1254Ter)

dbSNP: rs148043302
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001924251 SCV002206984 pathogenic Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome 2021-02-15 criteria provided, single submitter clinical testing This sequence change results in a premature translational stop signal in the GLI3 gene (p.Tyr1254*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 327 amino acids of the GLI3 protein. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with clinical features of Pallister-Hall syndrome (Invitae). This variant disrupts the C-terminus of the GLI3 protein. Other variant(s) that disrupt this region (p.Thr1488Lysfs*23) have been determined to be pathogenic (PMID: 24736735). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. For these reasons, this variant has been classified as Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.